- Stocks
- Pharma & Healthcare
- RPG Life Sciences
RPG Life Sciences share price
NSE: RPGLIFEPharma & HealthcareDrug Manufacturers - Specialty & Generic
RPG Life Sciences at a glance
RPG Life Sciences (NSE: RPGLIFE) closed at ₹2,754.80 on 22 Oct 2026, down 2.31% on the day. With a market capitalisation of ₹4,556 Cr, it ranks 816th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 39.6× trailing earnings, against a return on equity of 11.5% in FY07. Over the past year the share price has risen 18.9%. Its 52-week range is ₹1,733.00 (23 Mar 2026) to ₹3,127.80 (25 Sep 2026); the last close is 11.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹196 Cr (+15.8% year on year) and net profit ₹31 Cr (+17.0%), on a consolidated basis. Promoters held 72.95% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹4,556 CrRank 816 on NSE
- P/E (trailing)
- 39.6×
- Price to book
- 0×FY07
- EPS (TTM)
- ₹72.34to Q1 FY27
- ROE
- 11.5%FY07
- ROCE
- 5.1%FY07
- Debt to equity
- 1.19FY07
- Net profit margin
- 6.9%FY07
- Book value / share
- ₹49.74FY07
- Dividend payout
- 26.1%FY07
- 52-week high
- ₹3,127.8025 Sep 2026
- 52-week low
- ₹1,733.0023 Mar 2026
- 1-year return
- +18.9%
- RSI (14-day)
- 45.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.31% | −2.5% | −0.3% | −7.7% | +18.9% |
RPG Life Sciences quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹173 Cr | ₹143 Cr | ₹169 Cr | ₹182 Cr | ₹180 Cr | ₹177 Cr | ₹196 Cr |
| Revenue YoY | — | — | — | — | +4.2% | +23.6% | +15.8% |
| Net profit | ₹35 Cr | ₹117 Cr | ₹26 Cr | ₹37 Cr | ₹22 Cr | ₹30 Cr | ₹31 Cr |
| Net profit YoY | — | — | — | — | −36.6% | −74.5% | +17.0% |
| Net margin | 20.2% | 82.0% | 15.6% | 20.3% | 12.3% | 16.9% | 15.7% |
| EPS | ₹21.12 | ₹70.96 | ₹15.90 | ₹22.28 | ₹13.38 | ₹18.08 | ₹18.60 |
RPG Life Sciences financials
| Item | FY06 | FY07 |
|---|---|---|
| Revenue | ₹144 Cr | ₹120 Cr |
| Operating profit | ₹28 Cr | ₹10 Cr |
| Net profit | ₹26 Cr | ₹8 Cr |
| EPS (₹) | ₹18.00 | ₹6.00 |
| Cash from operations | ₹0 Cr | ₹0 Cr |
| Total debt | ₹97 Cr | ₹85 Cr |
| Shareholders' equity | ₹66 Cr | ₹72 Cr |
RPG Life Sciences shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| Foreign institutions | 1.45% | 1.35% | 1.11% | 1.00% | 0.87% | 0.95% |
| Domestic institutions | 6.14% | 6.48% | 6.70% | 7.04% | 7.45% | 8.67% |
| Non-institutions | 19.46% | 19.22% | 19.24% | 19.01% | 18.73% | 17.42% |
RPG Life Sciences vs peers
The listed Pharma & Healthcare companies nearest to RPG Life Sciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| IOLCPIOL Chemicals and Pharmaceuticals | ₹173.27 | −0.76% | +80.5% | ₹5,086 Cr | 36.9 | — |
| RPGLIFERPG Life Sciences | ₹2,754.80 | −2.31% | +18.9% | ₹4,556 Cr | 39.6 | — |
| ZOTAZota Health Care | ₹1,304.00 | −0.76% | −12.1% | ₹4,516 Cr | — | — |
| JSLLJeena Sikho Lifecare | ₹360.05 | −0.40% | −51.3% | ₹4,475 Cr | 20.3 | — |
| NOVARTINDNovartis India | ₹1,810.70 | +2.71% | +224.4% | ₹4,471 Cr | 48 | — |
| ORCHPHARMAOrchid Pharma | ₹876.25 | +0.06% | +20.9% | ₹4,444 Cr | 214.2 | — |
| SMSPHARMASMS Pharmaceuticals | ₹434.55 | +0.59% | +59.0% | ₹4,070 Cr | 39 | — |
Ask anything about RPG Life Sciences
Pivot answers on the live chart with evidence you can check, and tests strategies against RPGLIFE's own history. Try: “Why has RPGLIFE moved over the last three months?” · “Backtest a 50-day moving-average crossover on RPGLIFE over five years” · “Compare RPGLIFE with IOLCP on margins and valuation”
Frequently asked questions about RPG Life Sciences
What is the share price of RPG Life Sciences today?
RPG Life Sciences (NSE: RPGLIFE) last closed at ₹2,754.80 on 22 Oct 2026. Its 52-week high is ₹3,127.80 and its 52-week low is ₹1,733.00.
What is the market cap of RPG Life Sciences?
RPG Life Sciences' market capitalisation is ₹4,556 Cr (₹4,556 Cr) at the 22 Oct 2026 close, ranking 816th among the NSE companies Pivot tracks.
What is the P/E ratio of RPG Life Sciences?
RPG Life Sciences trades at a trailing P/E of 39.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 39.
What is the ROE and ROCE of RPG Life Sciences?
Return on equity was 11.5% in FY07 and return on capital employed was 5.1% in FY07 (consolidated figures).
Is RPG Life Sciences a debt-free company?
No. RPG Life Sciences' debt-to-equity ratio was 1.19 in FY07, with total debt of ₹85 Cr.
What were RPG Life Sciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), RPG Life Sciences reported revenue of ₹196 Cr, +15.8% year on year, and net profit of ₹31 Cr, +17.0% year on year.
How has RPG Life Sciences stock performed over the last year?
RPG Life Sciences' share price has risen 18.9% over the past year, −7.7% over three months and −0.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of RPG Life Sciences?
As of 30 Jun 2026: promoters 72.95%, foreign institutions 0.95%, domestic institutions 8.67%, non-institutions 17.42%.
Who are RPG Life Sciences' competitors?
The listed Pharma & Healthcare companies closest to RPG Life Sciences by market cap are IOL Chemicals and Pharmaceuticals, Zota Health Care, Jeena Sikho Lifecare, Novartis India, Orchid Pharma and SMS Pharmaceuticals.
Is RPG Life Sciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out RPG Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on RPGLIFE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text